Vincristine (Vincristine) - Uses, Dosage and Side Effects

Vincristine for dogs and cats is a chemotherapy agent derived from the periwinkle plant (Vinca rosea). It is a vinca alkaloid and one of the most commonly used chemotherapy drugs in veterinary oncology.

In India, lymphoma is among the most frequently diagnosed cancers in dogs, and transmissible venereal tumour (TVT) remains a significant concern in free-roaming and unsterilised dog populations. Vincristine plays a central role in the treatment protocols for both conditions, making it one of the most prescribed oncology medications across Indian veterinary practices.

Vincristine works by interfering with microtubules, structures that cancer cells need to divide and multiply. By disrupting cell division, it helps slow or stop the growth of rapidly dividing cancer cells.

Vincristine works in cats through the same basic mechanism as in dogs, disrupting microtubule formation and preventing rapidly dividing cancer cells from completing cell division.

For feline lymphoma, vincristine is generally combined with other chemotherapy medicines rather than being used alone. Combination protocols allow medicines with different mechanisms of action to target cancer cells while reducing reliance on a single drug.

There is no single vincristine protocol because the vincristine dosage for dogs and treatment schedule depend on the cancer being treated and the chemotherapy protocol the vet selects. For lymphoma, vincristine is commonly included in multi-drug protocols such as CHOP-based chemotherapy.

Before each treatment, the veterinarian may assess the dog's physical condition and review blood tests, particularly the complete blood count (CBC), to determine whether treatment can be given safely.

For many canine chemotherapy protocols (such as lymphoma), vincristine is administered intravenously at approximately 0.5 to 0.7 mg/m², with the exact dose and interval determined by the overall protocol and the dog's clinical condition.

For canine transmissible venereal tumour (TVT), a commonly used regimen is vincristine sulfate at 0.025 mg/kg intravenously once weekly. Under veterinary oncology supervision, treatment is generally continued for 2-4 weeks after complete resolution of the visible tumour, with most dogs achieving complete remission after approximately 5 to 7 doses.

Vincristine for cats is also administered intravenously in a clinical setting. Cats receive the drug as part of combination chemotherapy protocols for lymphoma, most commonly the COP or modified CHOP protocols.

A commonly used vincristine dose for cats is 0.5 to 0.7 mg/m² intravenously, with the treatment repeated according to the selected chemotherapy protocol rather than at a fixed interval for every patient.

Cats require particularly careful dose calculation and monitoring because chemotherapy doses cannot simply be extrapolated from a dog's dose. The veterinarian may also adjust treatment if blood counts fall or if significant adverse effects develop.

Vincristine side effects in dogs and cats are generally less severe than those of other chemotherapy agents, but they require close monitoring throughout treatment.

Vincristine overdose in dogs causes severe peripheral neuropathy, profound bone marrow suppression, intestinal ileus (complete loss of intestinal movement), and potentially life-threatening infection from neutropenia. Vincristine has a narrow therapeutic margin. Dosing errors in oncology settings can have serious consequences. If accidental overdose is suspected, seek emergency vet oncology care immediately.

Cats are similarly vulnerable to vincristine overdose effects. Severe neurotoxicity, respiratory compromise, and haematological collapse can occur. Emergency hospitalisation with intensive supportive care is required. Contact your veterinary oncologist or the nearest 24/7 cat emergency care facility immediately if overdose is suspected in a cat undergoing treatment.

Vincristine is a cytotoxic drug. Urine and faeces from treated pets may contain trace amounts of the drug for up to 48 hours after injection. Wear disposable gloves when handling waste during this period and dispose of it hygienically. Wash your hands thoroughly after contact.

Monitor your pet closely for signs of infection, particularly fever, lethargy, or loss of appetite, as neutropenia (abnormally low white blood cell count) can develop 5 to 7 days after treatment. Avoid contact with other sick animals during active chemotherapy. Attend all scheduled blood monitoring appointments, as dose adjustments depend on haematological findings.

Contact your veterinary oncologist immediately if your pet develops fever above 39.5°C, collapse, severe lethargy, complete appetite loss, uncontrolled vomiting or diarrhoea, or significant weakness within 5 to 10 days of a Vincristine injection. These may indicate sepsis from neutropenia, a life-threatening complication of chemotherapy requiring emergency hospitalisation.

Also report any swelling, pain, or skin changes at the injection site, as these may indicate extravasation injury requiring urgent wound management.

Vincristine for dogs and cats is a cornerstone chemotherapy agent in veterinary oncology, used across treatment protocols for lymphoma, TVT, and other malignancies.

Consistent attendance at scheduled treatment and monitoring appointments, diligent home observation for side effects, and prompt reporting of any concerns to your veterinary oncologist are essential for safe and effective chemotherapy management.